The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder

Pavel Golubchik, Michal Rapaport, Abraham Weizman

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. The severities of ADHD, anxiety, and depression symptoms were assessed by means of the ADHD Rating Scale (ADHD-RS), Screen for Child Anxiety Related Emotional Disorders, and the Children's Depression Inventory. The severity of ADHD and depression symptoms was reduced significantly (P<0.0003 and P=0.046, respectively). No improvement in total anxiety symptoms was found, but a significant reduction was obtained in the school-related subscale of the Screen for Child Anxiety Related Emotional Disorders (P=0.0054). A positive correlation was found between the reductions in ADHD-RS and Children's Depression Inventory scores (r=0.59, P=0.039). MPH treatment may be safe, tolerable, and effective in alleviating depression and school-related anxiety symptoms in patients with AS and ADHD.

Original languageEnglish
Pages (from-to)289-293
Number of pages5
JournalInternational Clinical Psychopharmacology
Volume32
Issue number5
DOIs
StatePublished - 2017

Keywords

  • Anxiety
  • Asperger syndrome
  • Attention deficit/hyperactivity disorder
  • Children and adolescents
  • Methylphenidate

Fingerprint

Dive into the research topics of 'The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder'. Together they form a unique fingerprint.

Cite this